In a previous study of the role of immunological processes in the pathogenesis of gluten-sensitive enteropathy, we demonstrated that the intestinal mucosa of patients with this disorder responds to gluten challenge in vivo with a striking increase in IgA and IgM synthesis (Loeb, Strober, Falchuk, and Laster, 1971) . If this increase were causally related to the lesion of gluten-sensitive enteropathy, we might expect a certain portion of the post-challenge immunoglobulin to have antigliadin activity. In the present investigation, we have evaluated this possibility by first measuring jejunal immunoglobulin (IgA and IgM)synthesis inbiopsy specimens obtained from patients with gluten-sensitive enteropathy before and after a gluten challenge, and then measuring the fraction of this increase due to the synthesis of antigliadin antibody. The results indicate that biopsies from patients in remission do not produce antigliadin antibody, whereas biopsies from the same patients in exacerbation produce increased quantities of immunoglobulins, a large portion of which are antigliadin antibodies. 'Presented in part at the national meeting of the American
globulin synthesis is due in some part to the production of antigliadin antibodies is examined. Using an affinity chromatography technique it has been demonstrated that in six of seven patients with gluten-sensitive enteropathy approximately half of the net increase in IgA and IgM synthesis occurring after gluten challenge can be attributed to the synthesis of antigliadin antibody. These data strengthen the hypothesis that immunological phenomena are related to the pathogenesis of glutensensitive enteropathy.
In a previous study of the role of immunological processes in the pathogenesis of gluten-sensitive enteropathy, we demonstrated that the intestinal mucosa of patients with this disorder responds to gluten challenge in vivo with a striking increase in IgA and IgM synthesis (Loeb, Strober, Falchuk, and Laster, 1971) . If this increase were causally related to the lesion of gluten-sensitive enteropathy, we might expect a certain portion of the post-challenge immunoglobulin to have antigliadin activity. In the present investigation, we have evaluated this possibility by first measuring jejunal immunoglobulin (IgA and IgM)synthesis inbiopsy specimens obtained from patients with gluten-sensitive enteropathy before and after a gluten challenge, and then measuring the fraction of this increase due to the synthesis of antigliadin antibody. The results indicate that biopsies from patients in remission do not produce antigliadin antibody, whereas biopsies from the same patients in exacerbation produce increased quantities of immunoglobulins, a large portion of which are antigliadin antibodies. ' Presented in part at the national meeting of the American Federation for Clinical Research 2 May 1971, and at the Second Coeliac Sym- Patients with gluten-sensitive enteropathy in remission were studied both immediately before and after an oral gluten challenge of six to 12 days. In each study intestinal biopsies were obtained and incubated in vitro with "4C-L-leucine. The biopsy tissues were then homogenized and centrifuged to yield a supernatant containing newly synthesized protein. The supernatant was assayed for 14C-IgA and 14C-IgM by measuring the binding of labelled protein to bromacetyl cellulose-anti-immunoglobulin (BAC-anti-Ig) , and for the presence of antigliadin antibody by measuring binding of radiolabelled protein to gliadin-Sepharose affinity columns.
PATIENTS
Seven patients (two males and five females) with gluten-sensitive enteropathy in remission were studied. The patients ranged in age from 9 to 55 years. The diagnosis was made on the basis of clinical and laboratory response to gluten restriction and reintroduction, the presence of fat and D-xylose malabsorption, and the histological demonstration of villous flattening and plasma cell and lymphocyte infiltration of the proximal jejunal mucosa.
CONTROLS
Seven normal individuals (six males and one female), as well as one patient with hypogammaglobulinaemia, were studied. The control individuals ranged in age from 21 to 45 years, and none, except the 947 patient with hypogammaglobulinaemia, had clinical or laboratory evidence of malabsorption or maldigestion. Biopsies were obtained initially following two or three weeks on a gluten-free diet and again after two weeks on a gluten-containing diet. The purpose and possible hazards of the study were explained to all participants, and informed consent was obtained from each. CLINICAL 
PROCEDURES
Jejunal biopsies were obtained with a four-hole multipurpose biopsy instrument positioned near the ligament of Treitz under fluoroscopic examination (Brandborg, Rubin, and Quinton, 1959 ). An average of three specimens was obtained with each biopsy procedure. One specimen from each patient was fixed for microscopic examination. Specimens for study of immunoglobulin synthesis were placed immediately on iced aluminium foil and transferred to the incubation medium within five minutes after being obtained.
INCUBATION CONDITIONS
Biopsy specimens were incubated with l4C-L-leucine in a modified Krebs-Ringer buffer system and processed as previously described (Loeb et al, 1971; Falchuk and Strober, 1972 (Lowry, Rosebrough, Farr, and Randall, 1951 (Cuatrecasas, 1970) was employed to detect antigliadin activity.
In this technique a molecule is purified or assayed by passage over columns containing materials to which the molecule will specifically bind. The column is first charged with the solution to be assayed and then washed with appropriate buffers to remove nonspecifically bound substances; finally, the column is treated with reagents which release specifically bound molecules. In the present studies the affinity columns were composed of Sepharose 4B (Pharmacia, Uppsala, Sweden) to which was coupled fraction III of a peptic-tryptic digest of gliadin (prepared by the method of Frazer, Fletcher, Ross, Shaw, Sammons, and Schneider, 1959) or other proteins. The cyanogen bromide technique was used to link covalently the various proteins to the Sepharose (Cuatrecasas, 1970; Ax6n, Porath, and Ernback, 1967) . In the usual study, the proteinSepharose was placed into siliconized glass Pasteur pipettes to form small columns (0.5 x 2.5 cm). Supernatant from the biopsy homogenates was added to the columns and the latter were then washed with 0.1 % bovine serum albumin (BSA), 0.1 % fetal calf serum (FCS), or 0.1 % gelatin,' in sodium phosphate buffer 0.1 M, pH 7.2, to remove the bulk of unbound proteins. Finally, the columns were washed with 6 M guanidine to remove bound radiolabelled protein.
We observed that a small fraction of the total amount of radioactivity placed on protein-Sepharose columns was not eluted with phosphate buffer, regardless of the nature of the radiolabelled protein (eg, "1C-protein in homogenate, 125I-BSA, 1251-IGA), or the nature of the protein linked to the Sepharose (eg, BSA, gliadin digest). This radioactivity was, however, eluted with guanidine. It was apparent, therefore, that the guanidine eluate contained nonspecifically held radioactivity (ie, held on the column by mechanisms other than the specific interactions between antibody and antigen), as well as specifically bound radioactivity. To control for such nonspecific retention of radioactivity, affinity chromatography of homogenates on gliadin-Sepharose columns was always run in parallel with chromatography on control columns consisting of BSASepharose or bovine gamma globulin-Sepharose (BGG-Sepharose). Values for the labelled proteins released from the latter columns by 6 M guanidine were subtracted from the values obtained with the gliadin-Sepharose columns to obtain a value for radioactivity specifically bound to the gliadinSepharose columns. In a typical example (patient LM) 1692 counts were released from a BSA-Sepharose column with 6 M guanidine; simultaneously, ' The nature of the protein in the washing buffer did not appear to make a difference in the results obtained: comparable data were obtained regardless of which washing buffer was employed. 2547 counts were released from a gliadin-Sepharose column with 6 M guanidine; therefore a net of 855 counts was bound specifically to the gliadin-Sepharose column.
To exclude the possibility that various Sepharose preparations had differing capacities for nonspecific radioactivity, three separate control columns were prepared (keyhole limpet hemocyanin-Sepharose (KLH-Sepharose), BGG-Sepharose, and BSASepharose) and run in parallel with gliadin-Sepharose. Us;ng the homogenate from patient MN, the value obtained for antigliadin activity was not significantly different, whether BSA-, BGG-, or KLH-Sepharose was employed as the control column.
To ensure that human immunoglobulins would not preferentially bind nonspecifically to gliadin-, BGG-, or BSA-Sepharose, 125I4gA and 1251-IgM were prepared (Greenwood and Hunter, 1963) and passed over columns as outlined above. In each case more than 99.5 % of the added counts were eluted with the phosphate buffer. Less than 0.5 % of the added counts adhered nonspecifically to the columns and were subsequently eluted with 6 M guanidine. Thus neither the 1251-lgA nor the 125I-IgM bound preferentially to either column. The degree of nonspecific binding noted is in the range observed with the 14C-protein in the biopsy homogenates, suggesting that nonspecific adherence of radioactivity to Sepharose columns is independent of the molecular weight of the eluate and the protein on the Sepharose. COUNTING 
TECHNIQUE
Radioactivity was counted in a liquid scintillation spectrometer (Packard 3320, Chicago, Illinois). The BAC samples were counted directly on fibreglass filters placed in liquid scintillation vials containing 11 ml of a solution consisting of one part Liquifluor (New England Nuclear Corporation, Boston, Mass.), 5 parts Triton X-100, and 15 parts toluene. The guanidine samples were counted in 20 ml of this solution. Quenching was corrected for by the ratio of counts in two channels produced by an automatic external standard. Samples were counted so that the standard deviation of the observed counts was 1% or less.
IgA and IgM (hereafter referred to as the IgA and/or IgM incorporation value) by jejunal biopsy specimens are shown in figure 1. IgA and IgM incorporation values for specimens obtained from five of seven patients in remission were within or close to 1 standard deviation of the mean of values for 29 normal individuals (Falchuk and Strober, 1972) . All seven patients had a significant rise in both the IgA (p < 0.02) and IgM (p < 0.01) incorporation values after a gluten challenge for six to 12 days.
In contrast to the patient group, when eight control subjects were treated in a similar manner to the patients, that is, placed on a gluten-free diet for 14 to 21 days, biopsied, challenged with gluten and rebiopsied, no difference was detected between preand post-gluten challenge incorporation values (table I) . (Bancroft, 1957 (Taylor, Thomson, Truelove, and Wright, 1961; Heiner, Lahey, Wilson, Gerrard, Shwachman, and Khaw, 1962) . Though this finding was initially thought to be aetiologically significant, its importance was questioned when it was demonstrated that patients with gluten-sensitive enteropathy also had circulating antibodies to other food constituents (Taylor et al, 1961; Heiner et al, 1962;  Alarcon-Segovia, Herskovic, Wakim, Green, and Scudamore, 1964; Kenrick and Walker-Smith, 1970) . Recently, attention has been focused on antibody present in the intestinal secretions of patients with gluten-sensitive enteropathy since the presence of these antibodies in secretions implies their local synthesis. Katz, Kantor, and Herskovic (1968) found antibodies to a peptic-tryptic digest of gliadin in the stool and jejunal secretion of 12 patients with gluten-sensitive enteropathy, but not in specimens collected from normal or other control individuals. Ferguson and Carswell (1972) have confirmed that patients with this disorder do indeed have antigluten antibodies as well as other antifood substance antibodies in stool and jejunal secretions. However, these antibodies were also present in patients not having gluten-sensitive enteropathy, suggesting that they were not related to the disease process. A critical question raised by these studies of antibodies in secretion and stool concerns the origin of the antibody detected. It is possible that such antibodies are derived from the circulation and are not locally produced. In the present study we show that regardless of whether serum or secretion antibody is present or absent, patients with gluten-sensitive enteropathy and not normal persons can and do produce a local antibody response to gluten. The response occurs within the intestinal mucosa where the pathological process is taking place, and it occurs early during the gluten challenge. The role of locally produced antigliadin antibodies in the pathogenesis of gluten-sensitive enteropathy remains to be determined. Of central importance is the question of whether the synthesis of these antibodies represents the primary pathological event in glutensensitive enteropathy or whether the synthesis is a secondary phenomenon which does or does not mediate the tissue injury seen in these patients. Indeed the possibility exists that the intestinal mucosa may synthesize not only antigluten antibodies but also antimilk, and other antidietary antibodies.
The pathogenicity of the antigluten antibodies may be further elucidated employing an organ culture model system recently developed by us (Faichuk, Gebhard, Sessoms, and Strober, 1974) . We believe that the mucosal immune response may be conditioned by the presence of an immune response gene or of a cell surface receptor, which facilitates a local immune response. This possibility is supported by the presence of a high incidence (80-88 %) of histocompatibility antigen HLA-8 in patients with gluten-sensitive enteropathy (Falchuk, Rogentine, and Strober, 1972 
